Search - tctmd.com

Displaying 61 - 80 of 528

Sort: Relevancy | Date

Presentation TCT 2022

TCT 22: Clopidogrel versus Aspirin in the Chronic Maintenance Period Following Percutaneous Coronary Intervention in Patients with Acute Coronary syndrome: Subgroup Analysis of the HOST-EXAM trial

Presenter: Jeehoon Kang

September 17, 2022

CV Care Around Noncardiac Surgery: New ESC Guidelines

News Conference News ESC 2022

CV Care Around Noncardiac Surgery: New ESC Guidelines

Michael O'Riordan

September 07, 2022

P2Y12 Inhibitors Top Aspirin for Long-term Secondary Prevention: PANTHER

News Conference News ESC 2022

P2Y12 Inhibitors Top Aspirin for Long-term Secondary Prevention: PANTHER

August 29, 2022

Factor XIa Inhibitors Show Potential for Safer Anticoagulation After MI, Stroke

News Conference News ESC 2022

Factor XIa Inhibitors Show Potential for Safer Anticoagulation After MI, Stroke

August 28, 2022

Shorter DAPT Sufficient Even in Complex HBR Patients: MASTER DAPT

News Conference News EuroPCR 2022

Shorter DAPT Sufficient Even in Complex HBR Patients: MASTER DAPT

Yael L. Maxwell

May 17, 2022

TCTMD’s Top 10 Most Popular Stories for April 2022

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for April 2022

May 02, 2022

Managing AF Patients Undergoing PCI—Some Lingering Questions

News Conference News ACC 2022

Managing AF Patients Undergoing PCI—Some Lingering Questions

Michael O'Riordan

April 12, 2022

Bentracimab Swiftly Reverses Ticagrelor, Platelet-Function Study Affirms

News Conference News ACC 2022

Bentracimab Swiftly Reverses Ticagrelor, Platelet-Function Study Affirms

April 02, 2022

Clopidogrel Superior to ‘Divine’ Aspirin Monotherapy in Secondary Prevention

News Daily News

Clopidogrel Superior to ‘Divine’ Aspirin Monotherapy in Secondary Prevention

Michael O'Riordan

March 30, 2022

REMAP-CAP: Mixed Results for Antiplatelets in Critical COVID-19

News Daily News

REMAP-CAP: Mixed Results for Antiplatelets in Critical COVID-19

March 22, 2022

Another Win for Guided P2Y12 Therapy in ACS: Meta-analysis

News Daily News

Another Win for Guided P2Y12 Therapy in ACS: Meta-analysis

Yael L. Maxwell

December 24, 2021

No Benefit for Icosapent Ethyl, P2Y12 Inhibitors in Separate COVID-19 Trials

News Conference News AHA 2021

No Benefit for Icosapent Ethyl, P2Y12 Inhibitors in Separate COVID-19 Trials

November 15, 2021

Bentracimab Rapidly, Safely Reverses Ticagrelor in Early REVERSE-IT Data

News Conference News AHA 2021

Bentracimab Rapidly, Safely Reverses Ticagrelor in Early REVERSE-IT Data

Yael L. Maxwell

November 15, 2021

Magnetic Endoscopy Capsule Reveals GI Damage Surprises From Antiplatelets

News Conference News TCT 2021

Magnetic Endoscopy Capsule Reveals GI Damage Surprises From Antiplatelets

November 06, 2021

More DAPT Duration Data, More Calls to Tailor to Individual Patients

News Conference News TCT 2021

More DAPT Duration Data, More Calls to Tailor to Individual Patients

November 05, 2021

TCTMD’s Top 10 Most Popular Stories for September 2021

News Daily News

TCTMD’s Top 10 Most Popular Stories for September 2021

October 01, 2021

OAC Analysis From MASTER DAPT Raises No Red Flags for Shorter DAPT

News Conference News ESC 2021

OAC Analysis From MASTER DAPT Raises No Red Flags for Shorter DAPT

September 02, 2021

One-month Dual Antiplatelet Therapy Followed by Clopidogrel Monotherapy in Acute Coronary Syndrome:

Presentation ESC 2021

One-month Dual Antiplatelet Therapy Followed by Clopidogrel Monotherapy in Acute Coronary Syndrome:

Presenter: Hirotoshi Watanabe

August 31, 2021

In ACS, Clopidogrel Monotherapy After 1-Month DAPT Falls Short: STOPDAPT-2 ACS

News Conference News

In ACS, Clopidogrel Monotherapy After 1-Month DAPT Falls Short: STOPDAPT-2 ACS

August 30, 2021

MASTER DAPT: One Month's Enough in Patients at High Bleeding Risk

News Conference News ESC 2021

MASTER DAPT: One Month's Enough in Patients at High Bleeding Risk

August 28, 2021

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.